British Columbia Cancer Agency; University of British Columbia.
Blood. 2014 Jun 19;123(25):3851-2. doi: 10.1182/blood-2014-05-574293.
In this issue of Blood, Herrmann et al elegantly demonstrate that CD26 is a new, specific chronic myeloid leukemia (CML) stem cell biomarker that phenotypically distinguishes leukemic stem cells (LSCs) from normal hematopoietic stem cells (HSCs), and that it is a potential therapeutic target in CML.
在本期《Blood》中，Herrmann 等人精彩地证明了 CD26 是一种新的、特异性的慢性髓系白血病（CML）干细胞标志物，它在表型上可区分白血病干细胞（LSCs）和正常造血干细胞（HSCs），并且是 CML 的一个潜在治疗靶点。
